<DOC>
	<DOC>NCT02039505</DOC>
	<brief_summary>This study is a phase 3, multicenter, randomized, double-blinded, placebo-controlled, parallel-group study to examine the efficacy, safety, and pharmacokinetics of MLN0002 (Vedolizumab) in induction and maintenance therapy in Japanese patients with moderately or severely active ulcerative colitis.</brief_summary>
	<brief_title>Phase III Study of MLN0002 (300 mg) in the Treatment of Ulcerative Colitis</brief_title>
	<detailed_description>This study is a Phase 3, multicenter, randomized, double-blinded, placebo-controlled, parallel-group study to examine the efficacy, safety, and pharmacokinetics of intravenous Vedolizumab (300 mg) infusion in induction and maintenance therapy in Japanese patients with moderately or severely active ulcerative colitis/</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis, Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Vedolizumab</mesh_term>
	<criteria>1. Patients aged 15 to 80 years (inclusive) at the time of consent 2. Patients with a diagnosis of total or leftsided colitis established based on the Revised Diagnostic Criteria for Ulcerative Colitis issued by Research Group for Intractable Inflammatory Bowel Disease Designated as Specified Disease by the Ministry of Health, Labor and Welfare of Japan (2012) at least 6 months before the start of administration of study drug. 3. Patients with moderately or severely active ulcerative colitis as determined by baseline complete Mayo score of 6 to 12 (inclusive) with an endoscopic subscore of ≥2 4. In case of the patients who meet any of the following criteria; patients with ≥8year history of total or leftsided colitis, patients aged ≥ 50 years, or patients with a firstdegree family history of colon cancer, those whom the complication of colon cancer or dysplasia was ruled out by total colonoscopy at the start of study drug administration (Or the results from total colonoscopy performed within 1 year before giving consent are available). 5. Patients meeting the criteria for treatment failure below with at least one of the following agents received within the previous 5 year period before giving consent. Corticosteroids Resistance Dependence Intolerance Immunomodulators (azathioprine or 6mercaptopurine) Refractory Intolerance AntiTNFα antibodies Inadequate response Loss of response Intolerance 1. Patients whose partial Mayo score decrease by 3 points or more between screening and the start of study drug administration 2. Patients with an evidence of or suspected abdominal abscess or toxic megacolon 3. Patients with a history of subtotal or total colectomy 4. Patients with ileostomy, colostomy,or fistula, or severe intestinal stenosis 5. Patients who started 5aminosalicylic acid oral drug or probiotics treatment or 30 mg/day or less of oral corticosteroids within 13 days before initiation of study drug administration. If these drugs were used within 14 days before initiation of study drug administration, the dosage must have been changed or their use discontinued within 13 days before the initiation of study drug administration 6. Patients who have received 5aminosalicylic acid or corticosteroid enemas/suppositories, intravenous corticosteroid injections, or more than 30 mg/day of oral corticosteroids, medications for diarrheapredominant irritable bowel syndrome, or Chinese herbal medicine for the treatment of ulcerative colitis (e.g., Daikenchuto) within 13 days before initiation of the study drug administration 7. Patients who have received an antidiarrheal drug for at 4 or more days consecutively within 13 days before initiation of the study drug administration or an antidiarrheal drug within 7 days before initiation of the study drug administration 8. Patients who have received azathioprine or 6mercaptopurine within 27 days before initiation of the study drug administration. However, this shall not apply to patients who have received these drugs for 83 or more days before initiation of the study drug administration and continued the steady dose administration of the drugs for 27 or more days before initiation of the study drug administration 9. Patients who have received cyclosporin, tacrolimus, methotrexate, or tofacitinib or any study drugs for treatment of ulcerative colitis within 27 days before initiation of the study drug administration 10. Patients who have received adalimumab within 27 days before initiation of the study drug administration or any biological drugs other than adalimumab within 55 days before initiation of the study drug administration. Topical administration (such as intraocular implantation for treatment of agerelated maculopacy) is allowed 11. Patients who have received any live vaccinations within 27 days before initiation of study drug administration 12. Patients who have undergone intestinal resection within 27 days before initiation of study drug administration or those anticipated to require intestinal resection during the study 13. Patients who have received leukocytapheresis or granulocyte apheresis within 27 days before initiation of the study drug administration 14. Patients with an evidence of adenomatous colonic polyps that need to be removed at the start of study drug administration 15. Patients with a history or a complication of colonic mucosal dysplasia</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>